The New NAFTA is a missed opportunity for gender equality

The recent renegotiation of the North American Free Trade Agreement presented a unique opportunity to rethink the dominant model for governing international trade and investment. At the outset of the “New NAFTA” talks in August 2017, Foreign Affairs Minister Chrystia Freeland outlined the government’s priorities under the umbrella of a…
Read more

Big business asked for deregulation; Morneau delivered in spades

Earlier this year, the Chamber of Commerce released yet another report on how public protections and other regulatory requirements are undermining Canadian competitiveness—and how the government should go about deregulating to make life easier for businesses big and small. Though it wasn’t directly tied to the Trump administration’s massive gutting…
Read more

The New NAFTA – What’s the Deal with Energy?

In the aftermath of the USMCA negotiations, the Trudeau government chalked up two significant “wins” for environmental protection and Canadian sovereignty: the elimination of investor state dispute settlement (ISDS), at least in the Canada-U.S. context, and the disappearance of NAFTA’s so-called proportionality clause in the energy chapter. The latter is…
Read more

Why high U.S. drug prices matter to Canada

In the mid-1970s the average monthly cost of a cancer drug in the United States was about $100. By 1995 that cost had crept up to about $1,800 per month and today it is over $10,000. Similarly, while drugs for multiple sclerosis introduced in the mid-1990s cost about $8,000 per…
Read more

USMCA: Red tape for public safety regulators

The CCPA continues to carefully read through the nearly 2,000-page USMCA text. This blog, the third in a series on how the agreement differs from NAFTA, examines the agreement’s chapter on Good Regulatory Practices, a relatively new addition to so-called next generation trade deals. Stay tuned to this space for continued analysis…
Read more